Correspondence: serum neutralization of SARS-CoV-2 Omicron sublineages BA.1, BA.2 and BA.5 in lung transplant recipients receiving prophylactic tixagevimab/cilgavimab

被引：0

作者：

Eldin, Carole ^{[1
,2
]}

Nurtop, Elif ^{[1
]}

Coiffard, Benjamin ^{[3
,4
]}

Colombini, Nathalie ^{[5
]}

Ninove, Laetitia ^{[1
]}

Priet, Stephane ^{[1
]}

Barthelemy, Karine ^{[1
]}

Reynaud-Gaubert, Martine ^{[3
,4
]}

de Lamballerie, Xavier ^{[1
]}

机构：

[1] Aix Marseille Univ, Unite Virus Emergents, IRD 190, Inserm 1207,IRBA,Univ Corsica, Marseille, France

[2] Hop Nord Marseille, AP HP, Equipe Operat Hyg EOH, Com Lutte Contre Infect Nosocomiales CLIN, Marseille, France

[3] HM Hop Nord, Ctr Ressources & Competences Mucoviscidose CRCM Ad, Serv Pneumol & Equipe Transplantat Plum, AP HM, F-13015 Marseille, France

[4] Aix Marseille Univ, Marseille, France

[5] Aix Marseille Univ, North Hosp, Publ Hosp Marseille, Pharm Dept, Marseille, France

来源：

INFECTION | 2024年

关键词：

D O I：

10.1007/s15010-024-02258-1

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

引用

页码：1697 / 1700

页数：4

共 50 条

[1] Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
Bruel, Timothee
Hadjadj, Jerome
Maes, Piet
Planas, Delphine
Seve, Aymeric
Staropoli, Isabelle
Guivel-Benhassine, Florence
Porrot, Francoise
Bolland, William-Henry
Nguyen, Yann
Casadevall, Marion
Charre, Caroline
Pere, Helene
Veyer, David
Prot, Matthieu
Baidaliuk, Artem
Cuypers, Lize
Planchais, Cyril
Mouquet, Hugo
Baele, Guy
Mouthon, Luc
Hocqueloux, Laurent
Simon-Loriere, Etienne
Andre, Emmanuel
Terrier, Benjamin
Prazuck, Thierry
Schwartz, Olivier
NATURE MEDICINE, 2022, 28 (06) : 1297 - +
[2] Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies
Timothée Bruel
Jérôme Hadjadj
Piet Maes
Delphine Planas
Aymeric Seve
Isabelle Staropoli
Florence Guivel-Benhassine
Françoise Porrot
William-Henry Bolland
Yann Nguyen
Marion Casadevall
Caroline Charre
Hélène Péré
David Veyer
Matthieu Prot
Artem Baidaliuk
Lize Cuypers
Cyril Planchais
Hugo Mouquet
Guy Baele
Luc Mouthon
Laurent Hocqueloux
Etienne Simon-Loriere
Emmanuel André
Benjamin Terrier
Thierry Prazuck
Olivier Schwartz
Nature Medicine, 2022, 28 : 1297 - 1302
[3] Serum Neutralization of Omicron BA.5, BA.2 and BA.1 in Triple Vaccinated Kidney Transplant Recipients
Pedersen, Rune M.
Bang, Line L.
Tornby, Ditte S.
Nilsson, Anna C.
Nielsen, Christian
Madsen, Lone W.
Johansen, Isik S.
Sydenham, Thomas V.
Jensen, Thoger G.
Justesen, Ulrik S.
Vitved, Lars
Palarasah, Yaseelan
Bistrup, Claus
Andersen, Thomas E.
KIDNEY INTERNATIONAL REPORTS, 2023, 8 (03): : 667 - 671
[4] The viral fitness and intrinsic pathogenicity of dominant SARS-CoV-2 Omicron sublineages BA.1, BA.2, and BA.5
Shuai, Huiping
Chan, Jasper Fuk-Woo
Hu, Bingjie
Chai, Yue
Yoon, Chaemin
Liu, Huan
Liu, Yuanchen
Shi, Jialu
Zhu, Tianrenzheng
Hu, Jing-Chu
Hu, Ye-fan
Hou, Yuxin
Huang, Xiner
Yuen, Terrence Tsz-Tai
Wang, Yang
Zhang, Jinjin
Xia, Yao
Chen, Lin-Lei
Cai, Jian-Piao
Zhang, Anna Jinxia
Yuan, Shuofeng
Zhou, Jie
Zhang, Bao-Zhong
Huang, Jian-Dong
Yuen, Kwok-Yung
To, Kelvin Kai-Wang
Chu, Hin
EBIOMEDICINE, 2023, 95
[5] SARS-CoV-2 Omicron BA.1/BA.2 Neutralization up to 8 Weeks After PrEP With Sotrovimab or Cilgavimab/Tixagevimab
Stiasny, Karin
Weseslindtner, Lukas
Heinzel, Andreas
Camp, Jeremy V.
Oberbauer, Rainer
Reindl-Schwaighofer, Roman
TRANSPLANT INTERNATIONAL, 2022, 35
[6] Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
Yu, Jingyou
Collier, Ai-ris Y.
Rowe, Marjorie
Mardas, Fatima
Ventura, John D.
Wan, Huahua
Miller, Jessica
Powers, Olivia
Chung, Benjamin
Siamatu, Mazuba
Hachmann, Nicole P.
Surve, Nehalee
Nampanya, Felix
Chandrashekar, Abishek
Barouch, Dan H.
NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (16):
[7] Efficacy of Tixagevimab/Cilgavimab Prophylaxis and Vaccination on Omicron Variants (BA.1, BA.2, BA.5, and BQ.1.1) in Kidney Transplant Recipients
Bertrand, Dominique
Laurent, Charlotte
Lemee, Veronique
Lebourg, Ludivine
Hanoy, Melanie
Le Roy, Frank
Nezam, Dorian
Pruteanu, Diana
Grange, Steven
de Nattes, Tristan
Lemoine, Mathilde
Candon, Sophie
Guerrot, Dominique
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 18 (10): : 1343 - 1345
[8] Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
Tomokazu Tamura
Daichi Yamasoba
Yoshitaka Oda
Jumpei Ito
Tomoko Kamasaki
Naganori Nao
Rina Hashimoto
Yoichiro Fujioka
Rigel Suzuki
Lei Wang
Hayato Ito
Yukie Kashima
Izumi Kimura
Mai Kishimoto
Masumi Tsuda
Hirofumi Sawa
Kumiko Yoshimatsu
Yuki Yamamoto
Tetsuharu Nagamoto
Jun Kanamune
Yutaka Suzuki
Yusuke Ohba
Isao Yokota
Keita Matsuno
Kazuo Takayama
Shinya Tanaka
Kei Sato
Takasuke Fukuhara
Communications Biology, 6
[9] Comparative pathogenicity of SARS-CoV-2 Omicron subvariants including BA.1, BA.2, and BA.5
Tamura, Tomokazu
Yamasoba, Daichi
Oda, Yoshitaka
Ito, Jumpei
Kamasaki, Tomoko
Nao, Naganori
Hashimoto, Rina
Fujioka, Yoichiro
Suzuki, Rigel
Wang, Lei
Ito, Hayato
Kashima, Yukie
Kimura, Izumi
Kishimoto, Mai
Tsuda, Masumi
Sawa, Hirofumi
Yoshimatsu, Kumiko
Yamamoto, Yuki
Nagamoto, Tetsuharu
Kanamune, Jun
Suzuki, Yutaka
Ohba, Yusuke
Tabata, Kaori
Yokota, Isao
Matsuno, Keita
Takayama, Kazuo
Tanaka, Shinya
Sato, Kei
Fukuhara, Takasuke
COMMUNICATIONS BIOLOGY, 2023, 6 (01)
[10] In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
Touret, Franck
Baronti, Cecile
Pastorino, Boris
Villarroel, Paola Mariela Saba
Ninove, Laetitia
Nougairede, Antoine
de Lamballerie, Xavier
SCIENTIFIC REPORTS, 2022, 12 (01)

← 1 2 3 4 5 →